Home Blog Page 134

First Phosphate Reports Annual Meeting Results, Substantial Increase in Shareholder Base and Adoption of Advance Notice Policy

By
Advertorial Desk
-

Saguenay, Québec – Newsfile Corp. – September 1, 2026 – First Phosphate Corp (NASDAQ: PHOS) (CSE: PHOS) (OTCQX: FRSPF) (FSE: KD0) (“First Phosphate” or the “Company“) is pleased to report the voting results for the Company’s Annual General and Special Meeting of Shareholders (the “Meeting“) held on August 28, 2026.

Voting Results

Detailed voting results of the election of the Company’s board of directors (the “Board“) are set out below:

Nominee Votes For % For Votes Withheld % Withheld
John Passalacqua 65,681,593 99.52% 317,515 0.48%
Laurence W. Zeifman 63,839,049 96.73% 2,160,059 3.27%
Bennett Kurtz 65,673,958 99.51% 325,150 0.49%
Peter Nicholson 65,691,489 99.53% 307,619 0.47%
Peter Kent 64,335,301 97.48% 1,663,807 2.52%

All nominees, as set forth in the Company’s Management Information Circular dated July 29, 2026 (the “Circular“), were elected as directors of First Phosphate at the Meeting.

At the Meeting, shareholders also approved: (1) the number of directors to be fixed at five, (2) the appointment of Davidson & Company LLP as auditor of the Company for the ensuing year and authorizing the Board to fix the remuneration of the auditor, (3) the Company’s advance notice policy (the “Policy“); and (4) the re-approval of the Company’s omnibus equity incentive plan, all as more particularly described in the Circular.

Matter Votes For % For Votes Against – Withheld % Against – Withheld
Number of directors 65,594,446 99.39% 404,662 0.61%
Appointment of auditors 64,206,061 97.28% 1,793,047 2.72%
Advance Notice Policy 64,112,942 97.14% 1,886,166 2.86%
Re-Approve Equity Incentive Plan 63,654,831 96.45% 2,344,277 3.55%

For further information regarding the matters considered at the Meeting, readers are encouraged to review the Circular, a copy of which is available under the profile for the Company on SEDAR+ (www.sedarplus.ca).

Increase in Shareholder Base

The Company is pleased to announce that its shareholders on record for the 2026 Meeting increased by 861% over the 2025 Meeting. The total registered shareholders reported are based on the registrar of the Company’s transfer agent plus beneficial shareholders reported by Broadridge.

AGM Record Date Shareholders
2026 12,501
2025 1,301
2024 861
2023 800
2022 307

The Company believes that this increase in shareholders represents a positive sign of maturation in the Company’s corporate development, one that can be attributed to successful financings, management’s commitment to results, and a broader understanding and appreciation of the Company’s vision, initiatives and opportunities, among both retail and institutional investors.

Advance Notice Policy

The Board has, effective immediately, adopted the Policy which, among other things, and subject to certain exceptions, sets forth a procedure requiring advance notice to the Company by any shareholder who intends to nominate any person for election as director of the Company at a meeting of shareholders at which directors are to be elected. For additional details, please consult the full text of the Policy included in the Circular.

The Board believes that the Policy provides a clear and transparent process for all shareholders to follow, if they intend to nominate directors, by providing a reasonable time frame for shareholders to notify the Company of their intention to nominate directors and requiring shareholders to disclose information concerning proposed nominees that is mandated by applicable securities laws.

The Policy enables the Board to evaluate the proposed nominees’ qualifications and suitability as directors and respond as appropriate in the best interests of the Company.

About First Phosphate Corp

First Phosphate (NASDAQ: PHOS) (CSE: PHOS) (OTCQX: FRSPF) (FSE: KD0) is a mineral exploration and development and clean technology company dedicated to building and reshoring a vertically integrated mine-to-market supply chain for the production of LFP batteries in North America. Target markets include energy storage, data centers, robotics, mobility, and national security. First Phosphate’s flagship Bégin-Lamarche property, located in Saguenay-Lac-Saint-Jean, Québec, Canada, represents a rare North American igneous phosphate resource producing high-purity phosphate characterized by very low levels of impurities.

For additional information, please contact:

Bennett Kurtz
Chief Financial Officer
Tel: +1 (416) 200-0657

Investor Relations: https://firstphosphate.com/investors
General Inquiries: https://firstphosphate.com/contact
Website: www.FirstPhosphate.com

Follow First Phosphate:
X: https://twitter.com/FirstPhosphate
LinkedIn: https://www.linkedin.com/company/first-phosphate/

-30-

Forward-Looking Information and Cautionary Statements

This news release contains certain statements and information that may be considered “forward-looking statements” and “forward looking information” within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking statements and forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved” and other similar expressions. In addition, statements in this news release that are not historical facts are forward looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include development and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. These statements are based on a number of assumptions including, among other things: that engineering and construction timetables and capital costs for the Company’s, exploration, development and expansion projects are correctly estimated and not affected by unforeseen circumstances; the ability to obtain financing for its proposed operations on acceptable terms; no material deterioration in general business and economic conditions; no material delays in obtaining permits and other approvals; no significant disruptions affecting the activities of the Company or its ability to access required project equipment and services, and operating supplies in sufficient quantities and on a timely basis; inflation and prices for Company project inputs being approximately consistent with anticipated levels; the ability to complete the exploration and development programs consistent with the Company’s expectations; commodity price expectations including assumptions for P2O5; the Company’s relationship with local municipalities and First Nations remaining consistent with the Company’s expectations; the Company’s relationship with other third-party partners and suppliers remaining consistent with the Company’s expectations; and government relations and actions being consistent with Company expectations. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. The Company does not assume any obligation to update or revise its forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law. All forward-looking information contained in this release is qualified by these cautionary statements.

The issuer is solely responsible for the content of this announcement.

About First Phosphate Corp.

TRUMPF makes glass substrates ready for the next generation of AI chips

By
Advertorial Desk
-

The future of AI chips is increasingly being shaped by packaging // With its HiPIMS product line, TRUMPF is addressing a key challenge facing the semiconductor industry: the reliable coating of highly complex glass substrates for the next generation of high-performance AI processors.


DITZINGEN, GERMANY / TAIPEI, TAIWAN – Media OutReach Newswire – 1 September 2026 – The race for more powerful AI chips is increasingly shifting to packaging. To pack more computing power into a smaller space in the future, industry leaders are therefore investing in new substrate technologies such as glass substrates. These enable more functions to be integrated into a smaller space and allow data to be transmitted faster and more efficiently within the chip. To achieve this, however, manufacturers must drill millions of microscopic holes into the glass and then coat them with conductive material.

Millions of through-holes must be error-free

TRUMPF has now developed the first industrial process of its kind that enables the production of such structures with high quality and reproducible results. With its HiPIMS products, the high-tech company is supporting the semiconductor industry in bringing glass substrates for the next generation of high-performance AI processors to series production. “The computing power of modern AI chips is increasing rapidly. As a result, the demand for packaging is also growing. Through-glass vias are considered a promising approach for future generations of chips. However, it is crucial that millions of extremely fine structures can be reliably coated. This is exactly where our HiPIMS technology comes into play,” says Piotr Lach, Head of Next Technology Demands at TRUMPF Elektronik. The challenge: The holes in the glass substrates are both very deep and very narrow. Even a small number of incorrectly coated through-vias can render an entire glass panel unusable.

For mass production, therefore, reliable processes, consistent results, and a high yield of functional components are crucial. TRUMPF’s technology improves process stability and increases production yield compared to conventional methods. This enables TRUMPF to help chip manufacturers economically transition new packaging concepts for AI applications into series production.

HiPIMS products precisely direct charged particles into deep structures

HiPIMS is a particularly high-performance coating process. TRUMPF’s industrially manufactured HiPIMS generators produce a highly ionized plasma with a higher proportion of electrically charged particles than conventional methods. These ions can be precisely controlled using additional electric and magnetic fields and directed into deep, narrow structures. This results in a significantly more uniform coating, even in deep trenches.

HiPIMS generates significantly higher ionization, leading to a higher density of deposited molecules. “This improves the quality of the coating. The technology helps increase manufacturing yield and lays the foundation for cost-effective mass production of future AI chips,” says Lach.

A Pioneer in the Industry

TRUMPF has many years of experience with HiPIMS technologies in industrial production environments. The company launched its first HiPIMS solutions for other application areas many years ago and has continuously refined the technology. Today, this high-tech company has extensive experience gained from real-world manufacturing processes.

“For our customers, it’s not just about technological performance. What matters most is that processes can be scaled and replicated consistently worldwide. With our industrialization expertise and technological lead, we support leading chip manufacturers in bringing advanced packaging technologies into mass production quickly and reliably,” says Lach.

TRUMPF covers several key technologies for advanced packaging

In addition to HiPIMS, TRUMPF offers other technologies for advanced packaging. These include ultrashort-pulse lasers for the production of through-glass vias, as well as plasma power supplies for coating and etching processes in semiconductor manufacturing. Together, these technologies form an important foundation for the production of high-performance chips for artificial intelligence, data centers, and high-performance computers.

Please click here to download the media kit.

Digital photographs in print-ready resolution are available to illustrate this press release. They may only be used for editorial purposes. Use is free of charge when credit is given as “Photo: TRUMPF”. Graphic editing – except for cropping out the main motif – is prohibited. Additional photos can be accessed at the TRUMPF Media Pool.

Hashtag: #TRUMPF

The issuer is solely responsible for the content of this announcement.

TRUMPF

TRUMPF is a high-tech company offering manufacturing solutions in the fields of machine tools, laser technology and semiconductor industry. It drives digital connectivity in manufacturing through consulting, platform products and software. TRUMPF is one of the technology and market leaders in highly versatile machine tools for sheet metal processing, in the field of industrial lasers and power electronics.

In 2025/26, TRUMPF employed 16,960 people and generated sales of 4.3 billion euros. With about 90 companies, the TRUMPF Group is represented in nearly every European country as well as in North America, South America and Asia. The company has production facilities in Germany, France, the United Kingdom, Italy, Austria, Switzerland, Poland, the Czech Republic, the United States, Mexico and China.

Find out more about TRUMPF at

Semicon Taiwan: TRUMPF Enables Integrated Chip Cooling for the Next Generation of AI Chips

By
Advertorial Desk
-

Advanced packaging requires integrated cooling at the semiconductor level // TRUMPF uses ultrashort-pulse lasers to enable the industrial production of the microstructures needed for this // Ultra-fine structures are created directly within the chip stack


DITZINGEN,GERMANY / TAIPEI,TAIWAN – Media OutReach Newswire – 1 September 2026 – The next generation of high-performance AI chips requires new cooling solutions. At Semicon Taiwan, TRUMPF is showcasing for the first time a new ultrashort-pulse laser application that enables the industrial production of cooling systems integrated into AI chips. “Heat dissipation will become the bottleneck for future AI processors. Without new cooling concepts, the high requirements cannot be met. Our ultrashort-pulse lasers enable the cost-effective production of the microstructures required for this on an industrial scale,” says Cathrin Conrad, Business Development Manager at TRUMPF and responsible for chip cooling. With the new laser application, chip manufacturers can flexibly integrate cooling structures into the chip stack. The process is suitable for various materials, such as silicon carbide and diamond.

AI Boom drives demand for new cooling concepts

Manufacturers are increasingly turning to advanced packaging, a cutting-edge semiconductor technology in which chips are stacked or closely interconnected to enable greater computing power in a small space. As a result, heat is increasingly generated inside the chip stack and can only be dissipated to a limited extent using conventional cooling methods, such as cooling server racks or entire data centers. Leading semiconductor manufacturers have therefore included novel cooling solutions for chips in their development roadmaps, such as microfluidic cooling or heat spreaders. This involves incorporating extremely fine structures into the chip package that dissipate heat where it is generated.

Semiconductor manufacturers must integrate these cooling structures into materials such as silicon carbide. This material is suitable for demanding applications in the semiconductor industry and efficiently dissipates heat. However, manufacturing the required microstructures poses major challenges for the semiconductor industry, as silicon carbide is extremely hard, the required structures are extremely small, and they are difficult to produce using established etching processes.

TRUMPF lasers enable industrial production of cooling structures

This is where TRUMPF’s ultrashort-pulse lasers (USP) come into play. “The key advantage of our technology: It is the combination of high laser power, beam-shaping technology, and our many years of application expertise that makes the industrial production of integrated cooling systems in chip stacks possible,” says Conrad.

The USP lasers ablate the silicon carbide with micrometer precision and create the fine structures. High precision is crucial for reliable cooling. Compared to etching, ultrashort-pulse lasers enable at least five times the processing speed while delivering excellent surface quality and precise geometry of the cooling structures. This allows the semiconductor industry’s requirements for both quality and cost-effectiveness to be met simultaneously. After all, in addition to quality, productivity plays a central role for chip manufacturers.

Please click here to download the media kit.

Digital photographs in print-ready resolution are available to illustrate this press release. They may only be used for editorial purposes. Use is free of charge when credit is given as “Photo: TRUMPF”. Graphic editing – except for cropping out the main motif – is prohibited. Additional photos can be accessed at the TRUMPF Media Pool.

Hashtag: #TRUMPF

The issuer is solely responsible for the content of this announcement.

TRUMPF

TRUMPF is a high-tech company offering manufacturing solutions in the fields of machine tools, laser technology and semiconductor industry. It drives digital connectivity in manufacturing through consulting, platform products and software. TRUMPF is one of the technology and market leaders in highly versatile machine tools for sheet metal processing, in the field of industrial lasers and power electronics.

In 2025/26, TRUMPF employed 16,960 people and generated sales of 4.3 billion euros. With about 90 companies, the TRUMPF Group is represented in nearly every European country as well as in North America, South America and Asia. The company has production facilities in Germany, France, the United Kingdom, Italy, Austria, Switzerland, Poland, the Czech Republic, the United States, Mexico and China.

Find out more about TRUMPF at www.trumpf.com

Sino Land reports 13.3% revenue growth and a 14.2% increase in net profit attributable to shareholders for FY2025/26

By
Advertorial Desk
-

Awarded first pilot area in the Northern Metropolis, demonstrating the Group’s confidence in Hong Kong’s prospects


Summary of 2025/2026Annual Results

  • The Group’s revenue for the year ended 30 June 2026 (“Financial Year”) was HK$9,273 million (2024/25: HK$8,183 million), representing an increase of 13.3% year-on-year. The Group’s net profit attributable to shareholders was HK$4,589 million (2024/25: HK$4,019 million).
  • Stable final dividend at HK43 cents per share (2024/25: HK43 cents per share). Together with the interim dividend of HK15 cents per share, the total dividend for the Financial Year is HK58 cents per share.
  • Attributable segment profit from property sales for the Financial Year, including share from associates and joint ventures, was HK$1,103 million (2024/25: HK$1,021 million), representing an increase of 8.0% year-on-year.
  • Total contracted sales in Hong Kong, including projects managed by our joint venture partners, exceeded 3,500 units during the Financial Year, generating HK$12.1 billion in attributable sales proceeds. The recent positive sales momentum was driven by the well-received launches of Grand Mayfair III, ONE PARK PLACE and La Mirabelle I.
  • During the Financial Year, the Group acquired three sites in Jordan Valley, Tuen Mun, and Kam Sheung Road Station, demonstrating our confidence in Hong Kong’s long-term prospects and our disciplined and strategic approach to land bank replenishment.
  • Subsequent to the Financial Year, the Group, together with its cross-sector joint venture partners, was awarded the development project for the first pilot area within the Hung Shui Kiu/Ha Tsuen New Development Area (the ‘HSK Pilot Area’) in the North Metropolis. This demonstrates our confidence in Hong Kong and aligns with the strategic directions of the National 15th Five-Year Plan, which states the accelerated development of the Northern Metropolis as a key priority of Hong Kong’s future growth engine. It is believed that the cross-sector collaboration will bring together diverse expertise and contribute to the region’s innovation and technology development.

Results and Business Highlights

HONG KONG SAR – Media OutReach Newswire – 1 September 2026 – Sino Land Company Limited (Stock Code: 83) today announced its annual results for the year ended 30 June 2026 (“Financial Year”). The Group’s underlying profit attributable to shareholders, excluding the effect of fair-value changes on investment properties for the Financial Year, was HK$4,789 million (2024/25: HK$5,118 million). Underlying earnings per share was HK$0.51 (2024/25: HK$0.58).

Hung Shui Kiu Ha Tsuen New Development Area first 'large-scale land disposal' project
Hung Shui Kiu Ha Tsuen New Development Area first ‘large-scale land disposal’ project

After taking into account the revaluation loss (net of deferred taxation) on investment properties of HK$192 million (2024/25: revaluation loss of HK$1,084 million), which is a non-cash item, the Group reported a net profit attributable to shareholders of HK$4,589 million for the Financial Year (2024/25: HK$4,019 million). Earnings per share for the Financial Year was HK$0.49 (2024/25: HK$0.45).

Property Sales –Robust sales momentum drives strong segment growth

Attributable segment profit from property sales for the Financial Year, including share from associates and joint ventures, was HK$1,103 million (2024/25: HK$1,021 million), representing an increase of 8.0% year-on-year. Market sentiment gained further traction in the first half of 2026, buoyed by supportive policies, an active financial market, and sustained inflows of talent and overseas students, collectively underpinning housing demand.

The Group won three land tenders during the Financial Year, namely New Kowloon Inland Lot No. 6674 in Jordan Valley, Tuen Mun Town Lot No. 569 in Tuen Mun, and the Kam Sheung Road Station Phase Two Property Development in Yuen Long. The Kam Sheung Road Station Phase Two project represents a major milestone in expanding our footprint in the Northern Metropolis. These strategic investments reflect our disciplined, selective approach to land acquisition, prioritising projects that offer good development value and sustainable returns while maintaining financial prudence.

As at 30 June 2026, the Group had over HK$6.6 billion in attributable contracted sales from projects already launched and sold but not recognised. Subsequent to the Financial Year, the Group launched selected units of La Mirabelle II in Tseung Kwan O, which received an encouraging market response. Together with La Mirabelle I, the two projects have recorded sales of over 1,060 units, reflecting healthy end-user demand and demonstrating market confidence in the quality and appeal of the Group’s residential developments.

Looking ahead, the Group has one new residential project scheduled for launch, namely the Wing Kwong Street/Sung On Street Development project. The launch timetable will be subject to the receipt of the relevant pre-sale consent and prevailing market conditions.

A diversified and balanced investment property portfolioreinforces long-term resilience

For the Financial Year, the Group’s attributable gross rental revenue, including share from associates and joint ventures, was HK$3,432 million (2024/25: HK$3,486 million), representing a 1.5% year-on-year decline. This decrease was primarily attributable to the continued challenging operating environment in the retail and industrial sectors, partly offset by increased contributions from the residential portfolio and improved office occupancy. Overall occupancy of the Group’s investment property portfolio improved to 90.0% during the Financial Year (2024/2025: 89.6%), representing an increase of 0.4 percentage point compared with last year, reflecting improved business sentiment and stronger tenant confidence.

Hong Kong remains well positioned to benefit from the Central Government’s ongoing support for deeper economic integration, the continued development of the Greater Bay Area and new growth drivers associated with the Northern Metropolis. To strengthen tenant sales and foot traffic, the Group continues to roll out targeted marketing and promotional campaigns while leveraging the growing Sports Economy to attract customers and enhance retail experience. These initiatives have delivered positive results, with the Group’s major flagship malls recording year-on-year growth in visitor traffic. The office sector is also showing encouraging signs of stabilisation supported by robust financial market activity and supportive government measures.

As at 30 June 2026, the Group has approximately 13.6 million square feet of attributable floor area of investment properties and hotels in the Chinese Mainland, Hong Kong, Singapore and Sydney.

Hotel Operations – Continuousimprovement in occupancy rates

For the Financial Year, the Group’s hotel revenue, including attributable share from associates and joint ventures, was HK$1,565 million compared to HK$1,506 million in the last year, and the corresponding operating profit was HK$519 million (2024/25: HK$475 million).

Tourist arrivals to Hong Kong continued to recover steadily in the first half of 2026, supported by the HKSAR Government’s ongoing efforts to promote integrated culture, sports and tourism initiatives. With a strong pipeline of mega-events and the opening of the new Terminal 2 at Hong Kong International Airport, the Group remains positive in the outlook for Hong Kong’s tourism sector.

With solid fundamentals and a strong balance sheet, the Group is well–positioned to capitalise on opportunities

“Hong Kong’s economy demonstrated encouraging momentum in the first half of 2026, supported by vibrant capital market activity, resilient external trade and continued growth in visitor arrivals. Real GDP expanded by 5.1% year-on-year, marking the strongest half-year growth in nearly five years, while IPO fundraising reached a five-year high in the first half of the year. The improving macroeconomic environment supported steady performance across key sectors of the economy.

The HKSAR Government is formulating Hong Kong’s first Five-Year Plan, which is expected to provide a strategic roadmap for the city’s long-term development, strengthen its competitive advantages and create new growth opportunities, with particular emphasis on the Northern Metropolis. In line with the National 15th Five-Year Plan, which states the accelerated development of the Northern Metropolis as a key priority of Hong Kong’s future growth engine, the Group, together with our distinguished corporate partners, was honoured to be awarded the HSK Pilot Area project. We have full confidence in Hong Kong’s prospects and hope that, through cross-sector collaboration, we can help bring together diverse expertise to contribute to the region’s innovation and technology development. In the HKSAR Government’s first Five-Year Plan, the Chief Executive also highlighted the pivotal role of the Northern Metropolis in enriching the housing ladder and creating more opportunities and space for home ownership. We are committed to bringing high-value industries and a quality living community to the Northern Metropolis, providing more housing and employment opportunities while enhancing connectivity between Hong Kong and cities across the Greater Bay Area.

Looking ahead, Hong Kong remains well positioned for continued growth, underpinned by vibrant financial market activity, successful talent attraction policies, growing international student enrolment, rising visitor arrivals and ongoing enhancements to cross-boundary transport infrastructure. The Group will continue to uphold prudent financial management and enhance operational efficiency. Supported by a solid financial position and forward-looking strategies, we are well positioned to navigate market fluctuations, capture growth opportunities, and create long-term value for our stakeholders,” said Mr. Daryl Ng Win Kong, Chairman of Sino Land.

Hashtag: #SinoLand

The issuer is solely responsible for the content of this announcement.

Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy

By
Advertorial Desk
-

Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction

Paxalisib Was Well Tolerated as Monotherapy and in Combination with Checkpoint Inhibition

Kazia is Preparing to Advance Paxalisib Into a Phase 2 Clinical Study to Evaluate Paxalisib in Immunotherapy-Resistant MSS/pMMR Colorectal Cancer

SYDNEY, Sept. 1, 2026 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced new preclinical and translational data showing that its lead asset, paxalisib, reduced tumor burden, the total amount of cancer in the body, by 52% (p=0.035) in microsatellite stable (MSS) / proficient mismatch repair (pMMR) colorectal cancer. In a separate study, adding paxalisib to an existing immunotherapy drug reduced tumor volume by an additional 50%, compared with the immunotherapy alone (p=0.022). Across both studies, treatment was well tolerated, with no evidence of treatment-related toxicity.

Kazia is also advancing a next-generation translational biomarker program designed to characterize the molecular, immune and epigenetic signatures associated with paxalisib response. The program is intended to identify patients most likely to benefit, provide early measures of biological response, and support biomarker-driven clinical development of paxalisib in pMMR colorectal cancer. These emerging biomarker insights, together with the compelling preclinical findings and a differentiated mechanism of action, have been incorporated into a new patent filing covering aspects of paxalisib’s potential use in colorectal cancer, further strengthening the intellectual property foundation for the program as it advances toward clinical development.

“Colorectal cancer is one of the leading causes of cancer-related death, and its rising incidence among younger adults underscores the urgent need for new treatment approaches. Using a novel preclinical pMMR model, patient-derived tissue biopsies and single-cell spatial epigenetic profiling, we uncovered a potentially novel mechanism through which paxalisib reprograms the tumor microenvironment to enhance cancer immune visibility, identifying cancer-specific molecular and immune signatures that may explain this shift from immunotherapy-resistant to responsive. Paxalisib showed meaningful anti-tumor activity on its own, and in combination with immunotherapy produced substantially greater tumor reduction in a setting where checkpoint inhibitors have historically provided little benefit. These findings support advancing paxalisib into a Phase 2 study in this patient population, part of our broader strategy to reprogram tumor and immune biology and overcome resistance,” said Dr. Sudha Rao, Chief Scientific Officer, Kazia Therapeutics.

Patients with MSS/pMMR colorectal cancer account for approximately 85–90% of metastatic colorectal cancer cases. Unlike the smaller subset of colorectal cancers with microsatellite instability (MSI-H), which has shown meaningful response to immune checkpoint inhibitors, published clinical data show that checkpoint inhibitor monotherapy has provided little to no clinical benefit in patients with MSS/pMMR metastatic colorectal cancer. Paxalisib’s approach in this setting represents a potential first-in-class strategy, as, to the Company’s knowledge, no other PI3K/mTOR inhibitor has previously demonstrated meaningful activity in pMMR colorectal cancer.

The Company plans to launch a five-arm Phase 2 clinical trial evaluating paxalisib as a monotherapy in combination with pembrolizumab (Keytruda®) versus standard of care in pre-treated MSS/pMMR metastatic colorectal cancer. Patients will be randomized to one of five arms: paxalisib at 15mg; paxalisib at 15mg plus pembrolizumab, with or without biologic; paxalisib at 30mg; paxalisib at 30mg plus pembrolizumab, with or without biologic; or a standard-of-care comparator arm. The primary endpoint is safety and tolerability, with progression-free survival, overall response rate and overall survival as secondary endpoints. Enrollment is expected to begin in the first quarter of 2027, with full enrollment of all five arms anticipated by the end of 2027.

About Kazia Therapeutics

Kazia Therapeutics (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. The Company’s lead asset, paxalisib, is an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of over 15 clinical trials. A completed Phase 2/3 study in glioblastoma (GBM AGILE) was reported in 2024, and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval. Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy. Additionally, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020 and for atypical teratoid/rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class intracellular PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, as well as MSETC, a potentially first-in-class SETDB1 inhibitor program intended to restore immune signaling in tumors that have become resistant to immunotherapy, including checkpoint inhibitors. Both programs are currently in preclinical development. For more information, please visit www.kaziatx.com or follow us on X @KaziaTx.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements regarding: the potential therapeutic benefit of paxalisib in pMMR metastatic colorectal cancer; the significance of preclinical and translational findings, including the orthotopic and subcutaneous CRC models and CTC cluster data; the Company’s biomarker program and anticipated future disclosures; and the planned initiation and design of a Phase 2 clinical trial in pMMR metastatic CRC. Forward-looking statements are generally identified by words such as “anticipates,” “believes,” “expects,” “intends,” “plans,” “may,” “will,” “could,” “should,” “estimates,” “projects,” “potential,” and similar expressions. These forward-looking statements are based on management’s current expectations and assumptions as of the date of this press release and are subject to significant risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Such risks and uncertainties include, but are not limited to: the preliminary and preclinical nature of the data described, which may not predict clinical outcomes in humans; risks associated with the conduct, timing and enrollment of clinical trials; regulatory review and approval processes; reliance on third-party collaborators and trial sites; the Company’s ability to obtain, maintain and protect its intellectual property; general economic and market conditions; and the Company’s ability to maintain compliance with NASDAQ listing requirements.

For a more complete discussion of risks and uncertainties, please refer to the Company’s filings with the SEC, including the “Risk Factors” section of the Company’s most recent Annual Report on Form 20-F. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements are qualified in their entirety by this cautionary statement.

(Keytruda is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.)

Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer

By
Advertorial Desk
-

Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity

Three-Arm Expansion of the Ongoing TNBC Trial Will Evaluate Paxalisib Plus Fulvestrant, With Palbociclib, Versus Standard-of-Care

First Patient Expected By Year-End 2026 and Full Enrollment by End of 2027

SYDNEY, Sept. 1, 2026 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia” or the “Company”), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced new preclinical data demonstrating the safety and anti-tumor activity of paxalisib in HR+/HER2- breast cancer, including evidence that paxalisib resensitized CDK4/6 inhibitor-resistant tumors to standard-of-care therapy. Based on these findings, the Company is moving rapidly to expand its ongoing TNBC clinical trial into hormone receptor-positive (“HR+”), HER2-negative (“HER2-“) advanced breast cancer to evaluate this effect directly and filed a related provisional patent application.

“HR+/HER2- breast cancer accounts for approximately 60–70% of all breast cancer diagnoses, and we expect nearly 322,000 new cases in the U.S. alone this year,” said Dr. John Friend, Chief Executive Officer of Kazia Therapeutics. “That scale, combined with the persistent need for better options once patients progress on standard therapy, represents a significant area of unmet medical need where paxalisib may play a role. Our preclinical data showing statistically significant, additive antitumor activity when paxalisib is combined with standard-of-care therapy gives us strong confidence in this approach, and we are moving quickly to bring this combination into the clinic for these patients. With the completion of our recent financing, based on our current plans and projections, we now have the capital in place to fund this program through completion.”

In addition to these findings, paxalisib in combination with fulvestrant, and paxalisib in combination with fulvestrant and palbociclib, showed consistent safety and resulted in statistically significant reductions in tumor volume across preclinical models. Kazia has filed a patent that is supported by the Company’s preclinical findings and has identified a high-risk subset of metastatic HR+/HER2- breast cancer defined by a novel PI3K/mTOR biomarker, with tissue- and blood-based tests associated with poor survival. Extensive benchmarking studies show that paxalisib can resensitize treatment-resistant tumors to combination therapy through a distinct epigenetic mechanism, an effect not observed with gedatolisib, an FDA-approved intravenous PI3K/mTOR inhibitor, indicating a paxalisib-specific effect rather than a class effect. In a HR+ xenograft model, paxalisib in combination with fulvestrant and palbociclib reduced tumor burden without added toxicity and showed primary tumor growth inhibition comparable to gedatolisib in combination with the same regimen.

“Our extensive benchmarking shows that paxalisib is differentiated in targeting the PI3K/mTOR–epigenetic resistance axis and importantly, this is not a class effect,” said Dr. Sudha Rao, Chief Scientific Officer, Kazia Therapeutics. “Paxalisib’s unique attributes are uncovering a broader role for PI3K/mTOR beyond conventional cytoplasmic signalling, with alternative pathways that may drive metastatic disease and resistance. In HR+ breast cancer, we have identified a novel epigenetic PI3K/mTOR biomarker, with both liquid and tissue tests, that is enriched in patients with poor prognosis. This gives us the opportunity to enrich for the patients where this biology matters most and brings precision medicine to HR+ breast cancer.”

This benchmarking work is ongoing, and Kazia expects to present additional data later this year, including further cellular, molecular and epigenetic characterization of paxalisib relative to other PI3K/mTOR inhibitors.

Current development strategies in this setting have primarily focused on sequencing additional lines of endocrine therapy, targeted agents or antibody-drug conjugates after resistance emerges. Kazia’s preclinical findings suggest that paxalisib may address resistance mechanisms at an earlier biological level through epigenetic and transcriptional effects that extend beyond conventional PI3K/mTOR pathway inhibition.

Alongside its IP filing, Kazia is amending the protocol of its ongoing TNBC clinical trial to add a three-arm expansion evaluating paxalisib in patients with pre-treated HR+/HER2- metastatic breast cancer. Patients will be randomized to one of three arms: paxalisib at 15mg plus fulvestrant (hormone therapy), with CDK4/6 inhibitor palbociclib; paxalisib at 30mg plus fulvestrant, with palbociclib; or a standard-of-care comparator arm of fulvestrant. The primary endpoint is safety and tolerability, with progression-free survival, overall response rate and overall survival as secondary endpoints.

The Company expects sites for this expansion to be activated and the first patient enrolled before the end of 2026, with full enrollment anticipated by the end of 2027. Clinical updates are anticipated throughout 2027, with a full readout anticipated in 2028.

About Kazia Therapeutics

Kazia Therapeutics (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. The Company’s lead asset, paxalisib, is an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of over 15 clinical trials. A completed Phase 2/3 study in glioblastoma (GBM AGILE) was reported in 2024, and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval. Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy. Additionally, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020 and for atypical teratoid/rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class intracellular PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, as well as MSETC, a potentially first-in-class SETDB1 inhibitor program intended to restore immune signaling in tumors that have become resistant to immunotherapy, including checkpoint inhibitors. Both programs are currently in preclinical development. For more information, please visit www.kaziatx.com or follow us on X @KaziaTx.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements regarding: the potential therapeutic benefit of paxalisib in HR+/HER2- breast cancer; the significance of preclinical findings, including benchmarking studies relative to other PI3K/mTOR inhibitors; the Company’s plan to expand the ongoing TNBC clinical trial into HR+/HER2- advanced breast cancer; the expected timing of site activation, first patient enrollment and full enrollment; anticipated clinical updates and full data readout timelines; the Company’s biomarker program and anticipated future disclosures; and the sufficiency of the Company’s capital to fund the program. Forward-looking statements are generally identified by words such as “anticipates,” “believes,” “expects,” “intends,” “plans,” “may,” “will,” “could,” “should,” “estimates,” “projects,” “potential,” and similar expressions. These forward-looking statements are based on management’s current expectations and assumptions as of the date of this press release and are subject to significant risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Such risks and uncertainties include, but are not limited to: the preliminary and preclinical nature of the data described, which may not predict clinical outcomes in humans; the ability to successfully amend the existing trial protocol and activate new sites; risks associated with the conduct, timing and enrollment of clinical trials; regulatory review and approval processes; reliance on third-party collaborators and trial sites; the Company’s ability to obtain, maintain and protect its intellectual property; the Company’s future capital needs and ability to fund planned operations; general economic and market conditions; and the Company’s ability to maintain compliance with NASDAQ listing requirements.

For a more complete discussion of risks and uncertainties, please refer to the Company’s filings with the SEC, including the “Risk Factors” section of the Company’s most recent Annual Report on Form 20-F. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements are qualified in their entirety by this cautionary statement.

Malaysia’s Cybersecurity Leaders to Convene at the 34th Edition Cyber Security Summit Malaysia 2026

By
Advertorial Desk
-

Summit to Bring Together More Than 150 CISOs, CIOs, Government Officials and Cybersecurity Leaders to Explore Identity, Intelligence and Resilience

KUALA LUMPUR, Malaysia, Sept. 1, 2026 /PRNewswire/ — The 34th Edition Cyber Security Summit Malaysia 2026 will take place on 10 September 2026 at the InterContinental Kuala Lumpur, bringing together more than 150 senior cybersecurity leaders, CISOs, CIOs, government officials and technology decision-makers from across Malaysia’s public and private sectors. Held under the theme “Cyber Security Reimagined: Identity, Intelligence & Resilience”, the summit will provide a platform for industry leaders to discuss emerging threats, cybersecurity strategies, digital resilience and the technologies shaping Malaysia’s evolving security landscape. The event is organised by Exito Media Concepts.


The summit comes at a time when organisations across Malaysia are navigating an increasingly complex cyber threat landscape driven by digital transformation, cloud adoption, expanding attack surfaces and evolving regulatory requirements. As enterprises accelerate their digital initiatives, cybersecurity leaders are increasingly focused on strengthening identity security, protecting critical data, improving threat intelligence and building resilient digital infrastructure.

Malaysia’s digital economy continues to expand as organisations across financial services, retail, healthcare, government, IT, enterprise and other sectors adopt connected technologies and digital platforms. With cyber threats becoming more sophisticated, organisations are balancing innovation with data protection, regulatory compliance, identity management and operational resilience. This has made cybersecurity a strategic priority extending beyond traditional security functions and into enterprise-wide digital transformation.

The event comes at a time when identity has emerged as a critical component of enterprise security. Credential theft, multi-factor authentication bypasses and privilege escalation are creating new challenges for organisations operating across hybrid workforces, cloud platforms and increasingly distributed technology environments. As enterprises adopt Zero Trust architectures, cybersecurity leaders are also evaluating how identity and access management can be aligned with regulatory expectations and business requirements.

At the same time, artificial intelligence, cloud security, cyber resilience and emerging threats are reshaping how organisations approach cybersecurity. Security leaders are exploring ways to strengthen their defences through AI-driven security, Zero Trust frameworks, data protection, threat intelligence and resilient security architectures while preparing for an evolving regulatory environment.

The summit will provide an opportunity for senior executives, government representatives, cybersecurity experts and technology innovators to exchange insights, explore emerging solutions and discuss practical approaches to strengthening trust, resilience and secure digital transformation across Malaysia.

Event Overview

The 34th Edition Cyber Security Summit Malaysia 2026 is an invitation-only, in-person conference designed for senior cybersecurity, technology, risk, data and digital leaders from Malaysia’s public and private sectors.

Running from 9:00 am to 5:00 pm, the summit will feature expert-led presentations, strategic discussions, panel sessions, technology showcases and curated networking opportunities designed to encourage knowledge sharing and collaboration between cybersecurity leaders and technology providers.

The summit will focus on emerging cybersecurity challenges and practical strategies across areas including threat intelligence, data protection, regulatory developments, AI-driven security, cloud security, Zero Trust and cyber resilience.

Event Details

Date: 10 September 2026

Time: 9:00 am to 5:00 pm MYT

Venue: InterContinental Kuala Lumpur

Format: Invitation-only, in-person

Attendance: More than 150 senior cybersecurity leaders

Website: https://exito-e.com/cybersecuritysummit/malaysia/

Confirmed Speakers

The summit will feature cybersecurity, technology and government leaders from across Malaysia’s public and private sectors, including:

  • Major Ir. Ts. Dr. Surenthiran Krishnan, Staff Officer 2 Doctrine & Policy / AI Analyst, Malaysian Armed Forces
  • Nuraishah Mokhtar, Senior Principal Assistant Director, National Cyber Security Agency (NACSA), Malaysia
  • Serena See, Chief Information Officer, TGV Cinemas
  • Stephanie Liew, Independent Director, Top Glove
  • Mr. Girijesh Hanchate, Director of IT, Pacific Inter-link Sdn Bhd (PIL Group)
  • Ts. James Lai, Chairman, Malaysia IoT Association
  • Anwer Yusoff, Chief Information Security Officer, Sena Group of Companies
  • Ewout Dhont, Team Lead Solution Engineering, Guardsquare
  • Siva Ratanasingaram, Senior Sales Engineer, Sophos
  • Elaine Ng, Regional Enterprise Manager GCR & SEA, Fastly
  • Yoong Seng Lai, Solutions Architect, Southeast Asia & Korea, Veeam Software

Strategic Agenda: Key Discussion Themes

Zero Trust and Identity-First Security

Exploring why identity has become a primary attack surface, including the growing risks of credential theft, MFA bypass and privilege escalation, while examining how organisations can implement Zero Trust architectures across hybrid workforces, cloud platforms and co-location environments.

Strengthening Identity and Privileged Access Security

Examining approaches to managing identity and access across increasingly distributed technology environments, with a focus on privileged access governance and protecting high-value accounts and critical systems from both insider and external threats.

AI-Driven Security and Emerging Cyber Threats

Exploring how artificial intelligence is transforming cybersecurity, from threat detection and response to security operations, while examining the opportunities and risks presented by increasingly sophisticated cyber threats.

Cyber Resilience in an Increasingly Connected Enterprise

Understanding how organisations can strengthen resilience across digital infrastructure, cloud environments and critical systems by moving beyond traditional security approaches and preparing for evolving cyber risks.

Cloud Security and Secure Digital Transformation

Examining the security challenges associated with cloud adoption and digital transformation, while exploring strategies for protecting data, applications and infrastructure across modern enterprise environments.

Data Protection, Regulatory Compliance and Digital Trust

Exploring the evolving data protection and regulatory landscape in Malaysia and how organisations can align cybersecurity strategies with regulatory requirements while strengthening customer, employee and stakeholder trust.

PR Newswire is the Official Press Release Distribution Partner of the 34th Edition Cyber Security Summit Malaysia 2026.

About Exito Media Concepts

Exito, meaning “success”, is a B2B events and media organisation with more than 16 years of experience. Delivering B2B events across technology, digital transformation, cybersecurity, healthcare, manufacturing, financial services and other enterprise sectors, Exito creates platforms that encourage collaboration, support innovation and facilitate business engagement. The Cyber Security Summit forms part of Exito’s global event series held across multiple international markets.

For more details, visit: https://exito-e.com/cybersecuritysummit/malaysia/

Media Contact

Prakruthi Nayaka

Media & PR Executive, Exito Media Concepts

Email: prakruthi.nayaka@exito-e.com

Phone: +91 9482440958

Website: https://exito-e.com/cybersecuritysummit/malaysia/

TempraMed Signs Letter of Intent with CPO Greece for Exclusive Distribution of VIVI Products in Greece

By
Advertorial Desk
-

Distribution framework pairs TempraMed’s injectable medication-protection products with one of the largest, most established Greek pharmacy and healthcare distributors

Highlights:

  • LOI with CPO Greece includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Greece, subject to a definitive agreement.
  • Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year over year to maintain exclusivity.
  • Transfer pricing and the first-year minimum unit commitment will be negotiated and established in the definitive distribution agreement.
  • CPO Greece brings an established pharmacy division, local distribution infrastructure and experience representing international healthcare and consumer brands.
  • Adding and renewing agreements in markets outside the USA since Q4 2025 including: Panama, Mexico, S. Korea, Turkey, Saudi Arabia, Israel, Kuwait, Brazil, Europe (Benelux) and Greece

Toronto, Ontario–(Newsfile Corp. – September 1, 2026) – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) (“TempraMed” or the “Company“), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has signed a non-binding letter of intent (the “LOI“) dated July 30, 2026 with CPO Greece (“CPO“) regarding the proposed exclusive distribution of VIVI Cap™ and VIVI Epi™ in Greece.

Under the LOI, TempraMed proposes to appoint CPO as the exclusive distributor of VIVI Cap and VIVI Epi in Greece, subject to the execution of a definitive distribution agreement and CPO’s compliance with minimum purchase obligations. The specific transfer prices and first-year minimum unit commitment have not yet been finalized and are to be established in the definitive agreement.

To maintain the proposed exclusivity, CPO would be required to increase its total annual combined purchases of VIVI Cap and VIVI Epi by no less than 20% year over year. CPO Greece is part of CPO Group, an established importer, distributor and exclusive agent serving the health, beauty, personal-care and food sectors. Founded in 1928, the group represents a broad portfolio that includes pharmaceutical products as well as hospital, medical, analytical and dental supplies. TempraMed believes CPO’s pharmacy-market experience, local commercial relationships and distribution capabilities make it a strong prospective partner for the Company’s entry into Greece.

The proposed relationship supports TempraMed’s strategy of expanding through experienced local partners that can navigate country-specific pharmacy channels and build sustained product adoption. If a definitive agreement is completed, Greece would become an additional European market for two of TempraMed’s commercial medication-protection products.

“CPO Greece is exactly the kind of established, market-facing partner we want as we expand TempraMed’s global commercial footprint,” said Ron Nagar, Founder and CEO of TempraMed. “Its deep pharmacy-market experience and local distribution capabilities provide a strong foundation for introducing VIVI Cap and VIVI Epi across Greece. The proposed 20% annual purchase-growth requirement reflects our intention to build this relationship for scale, not simply market entry. We are focused on converting this LOI into a definitive agreement and, subject to completing that agreement and satisfying all applicable requirements, establishing Greece as a meaningful European market for TempraMed. This LOI reinforces our confidence in the global relevance of our passive, battery-free technology and its ability to address an important everyday need for patients using temperature-sensitive medications.”

About CPO Greece

CPO Greece is part of CPO Group, a leading importer, distributor and exclusive agent for high-quality products across the health, beauty, personal-care and food sectors. Founded in 1928, CPO Group has built a broad portfolio spanning mass-market goods, premium cosmetics, pharmaceutical products and hospital, medical, analytical and dental supplies. CPO Greece operates dedicated pharmacy, medical, consumer and export divisions and supports international brands through local market development, sales, distribution and logistics. For more information, visit www.cpogroup.gr.

About TempraMed Technologies Ltd.

TempraMed Technologies Ltd. is a global medical-device company with a portfolio of innovative, temperature-controlled medication-storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, TempraMed develops patented, FDA-registered thermal-insulation devices that operate continuously without batteries or external power. Its commercial product portfolio includes VIVI Cap™, VIVI Cap Smart™, VIVI Epi™, and VIVI Med™. TempraMed enables patients and healthcare providers to confidently manage temperature-sensitive medications anywhere, anytime.

Investors interested in learning more about TempraMed are encouraged to contact the Company at:

ir@tempramed.com
www.tempramed.com

Contact:
Julia Becker
Vice President, Capital Markets
T: +1 (604) 785-0850
E: julia@tempramed.com

Media:
Brenda Zeitlin
Vice President, Marketing
E: brenda@tempramed.com

Cautionary Statements
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR HAS OR DOES THE CSE’S REGULATION SERVICES PROVIDER.

This press release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “strategy,” “will” and similar expressions, or statements concerning events or conditions that may occur in the future.

Forward-looking statements in this press release include, without limitation, ; the negotiation, execution and timing of a definitive distribution agreement with CPO; the terms of any such agreement, including transfer pricing, minimum purchase obligations and the conditions of exclusivity; the appointment of CPO as exclusive distributor of VIVI Cap and VIVI Epi in Greece; the anticipated benefits of the proposed relationship; the Company’s strategy of expanding through local distribution partners and its ability to enter Greece and other European markets; the addition or renewal of distribution agreements in other jurisdictions; regulatory clearance and import requirements for the Company’s products in Greece consumer adoption of the Company’s products; and the Company’s ability to expand its commercial presence in Greece.

Forward-looking statements are based on the opinions, expectations and assumptions of management as of the date of this press release, including assumptions that the parties will successfully negotiate and execute a definitive distribution agreement on terms consistent with the LOI; that CPO will satisfy the conditions to exclusivity; that required regulatory approvals and import clearances will be obtained; and that demand for temperature-protection solutions for injectable medications will continue.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied, including: that the LOI is non-binding and there is no assurance that a definitive agreement will be entered into, or if entered into, that it will be on the terms contemplated by the LOI or within the timeframe anticipated; the risk that the parties may be unable to agree on transfer pricing, minimum purchase commitments or other material terms; the risk that CPO may not meet minimum purchase obligations or the 20% annual growth requirement, resulting in loss of exclusivity; regulatory approval and import requirements; competitive developments, market acceptance, general economic conditions, geopolitical risks, and other risks described in the Company’s public filings available on SEDAR+.

Except as required by applicable securities laws, the Company undertakes no obligation to update or revise publicly any forward-looking statements.

The issuer is solely responsible for the content of this announcement.

1...133134135...6,607Page 134 of 6,607